Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Date:3/11/2009

ide of Italy;
  • The European Medicines Agency (EMEA) granted Premacure AB orphan designation for Insmed's IPLEX(TM) for the prevention of retinopathy of prematurity (ROP) in neonates of less than 32 weeks of gestational age. Premacure AB intends to initiate a phase 2 multicenter trial for IPLEX(TM) in the ROP indication during the second quarter of 2009.
  • "The sale of our FOB assets to Merck represents a watershed moment for Insmed," said Dr. Geoffrey Allan, Ph.D., President and CEO Insmed. "This agreement demonstrates Insmed's world-class clinical capabilities, and provides us with a substantial cash infusion that positions us well for future growth. In the short-term, we expect to be cash neutral for the balance of 2009 as we continue moving ahead with our IPLEX(TM) programs for MMD and ALS. In addition, we intend to pursue a comprehensive and thoughtful analysis to determine the most appropriate use of the proceeds we will receive from Merck. Our objective, though, is to utilize this capital to grow our business, and create additional shareholder value, as we have done through the transaction with Merck."

    Financial Results for Fourth Quarter and Full-year 2008

    Revenues for the fourth quarter ended December 31, 2008 were $2.9 million, up from $2.1 for the corresponding period in 2007. The increase was mainly attributable to an $846,000 increase in cost recovery revenue from our EAP to treat patients with ALS in Italy.

    The net loss for the fourth quarter of 2008 was $4.0 million or $0.03 per share, compared with a net loss of $3.3 million or $0.03 per share in the fourth quarter of 2007.

    R&D expenses increased to $5.4 million from $4.6 million, reflecting an increase in clinical trial activity for our FOB and IPLEX(TM) programs. SG&A Expenses increased to $1.3 million from $0.9 million, du
    '/>"/>

    SOURCE Insmed Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
    2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
    3. Insmed to Appeal Delisting Notification From Nasdaq
    4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
    5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
    6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
    7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
    8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
    9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
    10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
    11. Insmed to Present at CBI Follow-On Biologics Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/16/2015)... MENLO PARK, Calif. , April 16, ... (DelMar and the Company), a biopharmaceutical company focused on ... drug indications, today announced that the Mayo Clinic ... trial site for the ongoing, multicenter Phase I/II study ... the most common and deadly form of human brain ...
    (Date:4/16/2015)... Md. , April 16, 2015  Northwest ... a biotechnology company developing non-toxic DCVax® personalized immune ... been included in the Loncar Cancer Immunotherapy Index ... investors better track the immunotherapy field within the ... have selected "the top 25 companies" in the ...
    (Date:4/16/2015)... April 16, 2015 Modality Solutions, ... systems for highly regulated industries, is pleased to ... a monthly columnist for Cold Chain IQ - ... ). His column titled, Global Cold Chain Connections, ... for today’s life sciences, pharmaceutical and healthcare supply ...
    (Date:4/15/2015)... OXFORD, England , April 16, 2015 /PRNewswire/ ... company developing novel biological drugs to treat cancer ... research and development arm of AstraZeneca, today announced ... Under the terms of the agreement, ... combining MedImmune,s investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or ...
    Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
    (Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
    (Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
    (Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
    Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
    ... While radiation treatments deliver precise doses of high-energy ... to shrink tumors, oncologists have become increasingly concerned ... treatments to nerves responsible for upper body mobility. ... UC Davis Cancer Center researchers have taken the ...
    ... Department of Statistics and Centre for Complexity Science have ... the complex cell interactions that lead to cancer and ... such as Facebook for useful insights. An approach ... gain an understanding of a range of systems with ...
    ... As polar bears adapt to a warming Arctica frozen seascape ... unlikely source: snow goose eggs. New calculations show that changes ... nesting near the western Hudson Bay could provide at least ... new analysis appears in Polar Biology . "Over ...
    Cached Biology News:UC Davis team refines cancer treatments to reduce potential nerve damage 2New tool could unpick complex cancer causes and help sociologists mine Facebook 2Goose eggs may help polar bears weather climate change 2
    Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
    ...
    Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
    Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
    Biology Products: